Ignite Creation Date:
2025-12-26 @ 11:14 AM
Ignite Modification Date:
2025-12-29 @ 5:47 PM
Study NCT ID:
NCT05878028
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2023-05-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Sponsor:
Quanli Gao
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
HenanCH L-TIL aNSCLC
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None